
|Videos|April 26, 2022
Novel Targeted Therapy for EGFR Exon 20–Positive NSCLC
Author(s)Zofia Piotrowska, MD, MHS
Comprehensive insight on the two novel, targeted agents approved for the management of EGFR exon 20–positive NSCLC following frontline therapy.
Advertisement
Case: A 59-Year-Old Female with Lung Cancer
Initial presentation
- BC is a 59 y/o Asian female who presents to her physician complaining of shortness of breath, fatigue, and persistent right- sided neck pain.
- BC believes she is experiencing neck pain because of her new sleeping pillow.
- Since her last examination 6 months ago, BC has lost close to 10 lbs. BC has not changed her eating habits or style.
- PMH: Hypercholesterolemia (controlled)
- SMH: no history of smoking; drinks socially
- FH: she lives with her partner and 2 dogs; mother passed away from ovarian cancer 3 years ago.
- PE: LLL auscultation reveals decreased breath sounds visible bruising
Clinical workup
- Current Labs:
- CBC panel: Normal
- Liver function/Renal function: Normal
- CT Chest: LLL primary, mediastinal LNs; bone metastases
- Diagnosis: Stage IV adenocarcinoma
- MRI brain is negative for brain metastases
- CT scan of abdomen and pelvis shows additional bone metastases
- Weight: 120 lbs (54.5 kg)
- Biopsy of mediastinal lymph nodes shows stage 4 lung adenocarcinoma
- PD-L1 55%
Treatment
- NGS has been ordered and the results are pending.
- Patient initiated on a chemotherapy doublet.
Advertisement
Related to this article

FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.

Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.

Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Novocure’s Optune Mya Gets FDA Not Approvable Letter
3
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
4
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
5
